Athyreosis

Athyreosis means a baby is born without any thyroid gland at all. Because the thyroid gland makes thyroid hormone, babies with athyreosis have primary congenital hypothyroidism from birth. Without early treatment, low thyroid hormone can harm brain development and growth. Newborn screening programs catch most cases in the first days of life so treatment can start right away and children can grow and learn normally. Athyreosis is one form of thyroid dysgenesis (abnormal thyroid development); others include an ectopic (misplaced) thyroid or a very small thyroid (hypoplasia). Genetic & Rare Diseases Center+2Orpha+2 During early pregnancy, the thyroid gland forms and moves to the neck. In athyreosis, this process fails completely, so no tissue is present. That anatomic absence—not a temporary problem—explains why athyreosis causes a permanent need for thyroid hormone replacement. In the broader condition “congenital hypothyroidism,” causes are usually thyroid dysgenesis or dyshormonogenesis (a gland is present but can’t make hormone). PMC+1

Athyreosis means a baby is born without a thyroid gland at all. The thyroid normally sits in the lower front of the neck and makes hormones (T4/T3) that guide brain development, growth, and metabolism. When the gland is missing, the baby has primary congenital hypothyroidism from birth because the body cannot make thyroid hormone on its own. Newborn screening (the heel-prick blood spot test) is designed to catch this very early so treatment can start quickly and protect the brain. In practice, athyreosis is one form of thyroid dysgenesis (abnormal development of the thyroid) and is less common than ectopic (misplaced) or hypoplastic (small) thyroid, but it is the most severe anatomically because there’s no thyroid tissue present. Diagnosis is confirmed with labs that show very high TSH and low T4, together with imaging (thyroid ultrasound and/or radionuclide scan) that finds no thyroid tissue; serum thyroglobulin is typically undetectable. Lifelong levothyroxine fully replaces the missing hormone and enables normal growth and neurodevelopment when started promptly after birth. PubMed+4PMC+4PMC+4

---

Other names

You may see athyreosis described as: thyroid agenesis, congenital athyreosis, thyroid aplasia, or complete absence of the thyroid. All refer to the same anatomic reality—no functioning thyroid tissue present. It sits within the spectrum of thyroid dysgenesis, which also includes ectopic and hypoplastic thyroid glands. Orpha+1

---

Types

Clinicians often discuss athyreosis alongside other structural forms of congenital thyroid underdevelopment to guide testing:

1. Athyreosis (thyroid agenesis) – complete absence of thyroid tissue. Typically: very high TSH, very low T4; ultrasound and scintigraphy show no gland; thyroglobulin is usually undetectable. Orpha+2JAMA Network+2

2. Ectopic thyroid – thyroid present but in an abnormal location (often at the tongue base); can make some hormone. Imaging shows uptake at the ectopic site. Oxford Academic

3. Thyroid hypoplasia – small underdeveloped thyroid in the normal neck location. Oxford Academic

4. Thyroid hemiagenesis – only one lobe develops; not true athyreosis but part of dysgenesis spectrum. Oxford Academic

These patterns are best separated with ultrasound plus radionuclide scanning, which together maximize diagnostic accuracy in congenital hypothyroidism. Oxford Academic+1

---

Causes and risk factors

Strictly speaking, “cause” means why the thyroid never formed. In many babies this remains sporadic and unexplained, but research points to gene variants and in-utero influences. Below are well-established causes and plausible risk factors backed by guideline and genetics literature:

1. Sporadic failure of thyroid organogenesis (most common): thyroid dysgenesis (including agenesis/athyreosis) accounts for ~80–90% of permanent primary congenital hypothyroidism overall. BioMed Central

2. Pathogenic variants in thyroid development transcription factors: NKX2-1 (TTF-1), PAX8, FOXE1, NKX2-5; these regulate early thyroid formation and migration. Variants can produce agenesis or severe hypoplasia. PubMed+1

3. Variants in the TSH receptor (TSHR) affecting trophic signaling to the developing gland; severe loss-of-function may result in absent or rudimentary tissue. PubMed

4. GLIS3 and other rare developmental genes occasionally linked to thyroid dysgenesis. PMC

5. Chromosomal or syndromic contexts (e.g., rare associations where thyroid dysgenesis is part of a broader malformation pattern). BioMed Central

6. In-utero vascular disruption hypothesis: transient vascular accidents during early organogenesis may prevent gland formation (inferred in dysgenesis literature). BioMed Central

7. Maternal iodine excess (rare)—can suppress fetal thyroid; classically causes transient hypothyroidism rather than agenesis, but severe effects during organogenesis may impair development. (Guidelines discuss iodine effects broadly in CH differentials.) PMC

8. Maternal iodine deficiency (population-level risk)—a major global cause of congenital hypothyroidism; typically yields goiter/dyshormonogenesis, yet severe deficiency during early gestation could contribute to abnormal development. Medscape

9. Maternal antithyroid drugs (e.g., methimazole) taken in early pregnancy—generally cause transient fetal hypothyroidism; included here as important differential/indirect developmental risk, though not a proven cause of agenesis. PMC

10. Maternal TSH receptor–blocking antibodies—cause transient neonatal hypothyroidism; useful comparator because imaging will show present (not absent) tissue. PMC

11. Consanguinity / recessive inheritance in some families with developmental gene variants. PubMed

12. Environmental teratogens (general concept from dysgenesis reviews; specific agents variably implicated). BioMed Central

13. Early embryologic migration failure of thyroid anlage (if severe, may mimic agenesis on imaging). Oxford Academic

14. De novo mutations (no family history) in key developmental genes—common in dysgenesis. PubMed

15. Epigenetic and polygenic influences suggested by variable penetrance across families. PubMed

16. Thyroid hemiagenesis progressing to functional “athyreosis” if the single lobe involutes or is nonfunctional—clinically relevant differential. Oxford Academic

17. Ectopic thyroid with involution or ablation in utero (rare explanatory hypothesis for apparent agenesis on postnatal imaging). Oxford Academic

18. Associated midline developmental anomalies (e.g., clefting, choanal atresia) occasionally co-occur with developmental gene variants. BioMed Central

19. Maternal illness and prematurity—increase risk of missed early test signals and need for repeat screening; included as an indirect factor in pathways to delayed diagnosis rather than causation of agenesis. Boston Children’s Answers

20. Population genetics hotspots for CH-related variants (e.g., DUOX2/TG/TSHR clusters in some cohorts), underscoring genetic susceptibility to severe thyroid underdevelopment or function loss. Frontiers

Items are important differentials for congenital hypothyroidism and influence testing strategy; true, proven causes of complete agenesis are mostly items 1–5, 11, 14. I’ve listed the broader set so you can see the full clinical context used during evaluation.

---

Common symptoms and signs

Most newborns with untreated congenital hypothyroidism look normal at birth, which is why newborn screening is essential. Without early treatment, signs emerge over days to weeks. Here are plain-language descriptions of typical features:

1. Prolonged newborn jaundice – yellow skin/eyes lasting longer than usual. BioMed Central

2. Poor feeding and sluggishness – baby seems very sleepy and feeds slowly. BioMed Central

3. Constipation – infrequent, hard stools. BioMed Central

4. Low energy and low muscle tone – the baby feels “floppy.” BioMed Central

5. Large soft spots on the skull (fontanels) – especially a widely open posterior fontanel. BioMed Central

6. Puffy face with coarse features (myxedematous facies) – characteristic, especially if untreated. BioMed Central

7. Big tongue (macroglossia) – may cause noisy breathing or a protruding tongue. BioMed Central

8. Hoarse cry – low-pitched, rough cry. BioMed Central

9. Cold, dry skin and cool body temperature – signs of slowed metabolism. Medscape

10. Umbilical hernia and abdominal distension – belly looks protuberant. BioMed Central

11. Slow heart rate (bradycardia) – sometimes with low-voltage ECG; more relevant beyond the immediate newborn period. Medscape

12. Feeding difficulty and poor weight gain – failure to thrive if untreated. BioMed Central

13. Slowed reflexes (especially ankle jerk relaxation) – a classic bedside clue in hypothyroidism. Medscape

14. Hearing problems – some infants with CH have hearing impairment, which is why hearing tests are part of care. PMC

15. Developmental delay (if treatment is delayed) – problems with motor milestones and cognition; early therapy prevents this. NCBI

---

Diagnostic tests

Evaluation follows a structured path: newborn screening → confirm with serum labs → start levothyroxine immediately → image the thyroid to define anatomy → add targeted tests where helpful. Below I group tests by category and explain what each shows.

A) Physical examination (bedside observations)

1. General newborn exam – looks for jaundice, puffy face, big tongue, large fontanel, umbilical hernia, hypotonia; these raise suspicion for CH but are not required to diagnose. BioMed Central

2. Cardiorespiratory check – slow heart rate or signs of low cardiac output can appear in hypothyroidism; clinicians correlate with labs and (if needed) echocardiography. jcrpe.org

3. Growth and anthropometry – weight/length/head circumference and early growth trajectory; important for monitoring treatment response over time. NCBI

4. Neurodevelopmental screen – simple bedside checks for tone, alertness, primitive reflexes; formal developmental screening continues during follow-up. NCBI

5. Neck palpation – in athyreosis there is no palpable thyroid tissue; palpation mainly helps detect a goiter or ectopic mass in other forms of CH. Oxford Academic

B) “Manual”/clinic-based tests (no major equipment)

6. Deep tendon reflex testing (Achilles relaxation time) – delayed relaxation suggests hypothyroidism; it’s a quick bedside sign used alongside labs. Medscape

7. Hearing screening referral (initial OAE set-up) – clinicians initiate newborn otoacoustic emission screening; if abnormal, proceed to ABR. PMC

8. Growth-chart plotting and serial head circumference – tracks catch-up growth after starting therapy (simple but critical longitudinal tool). NCBI

9. Temperature and skin assessment – hypothermia and dry, cool skin support the clinical picture, though not diagnostic alone. Medscape

10. Feeding assessment – structured observation of feeding/weight gain to ensure early treatment is effective. NCBI

C) Laboratory and pathological tests (confirmatory)

11. Newborn screening (heel-prick dried blood spot) – programs measure TSH and/or T4 typically at 24–48 hours after birth; abnormal screens trigger urgent confirmatory testing. AAP Publications+2PMC+2

12. Serum TSH and free T4 (confirmatory) – very high TSH with low free T4 confirms primary congenital hypothyroidism; this is the anchor diagnosis step. American Thyroid Association

13. Serum thyroglobulin (Tg) – undetectable or very low Tg strongly suggests athyreosis; higher levels point toward ectopic or dyshormonogenesis with present tissue. PubMed+1

14. Antithyroid antibodies (maternal/infant) – helps identify transient CH due to maternal TSH-blocking antibodies, which is not athyreosis and will have thyroid tissue present. ScienceDirect

15. Genetic testing (targeted panels / NGS) – looks for variants in PAX8, NKX2-1, FOXE1, NKX2-5, TSHR and others when athyreosis/dysgenesis is suspected or there is family history. Results inform counseling, though treatment is the same. PubMed+1

D) Electrodiagnostic / physiologic tests

16. Auditory Brainstem Response (ABR) – objective hearing test using scalp electrodes; infants with CH have higher rates of hearing abnormalities, so ABR is widely used when OAE is abnormal. PMC

17. Nerve conduction studies (NCS) – rarely needed in infants, but hypothyroidism can slow peripheral nerve conduction; used if neuropathy is suspected later. PMC

18. Electrocardiogram (ECG) – may show bradycardia or low voltage in hypothyroidism; studies in neonates are mixed, but ECG is used if there are cardiac concerns. Medscape+1

E) Imaging tests

19. Thyroid ultrasound (US) – first-line, noninvasive imaging of the neck; in athyreosis, no thyroid tissue is seen. Ultrasound helps distinguish agenesis from hypoplasia and from low-lying ectopic glands in the neck. Oxford Academic+1

20. Radionuclide thyroid scintigraphy (I-123 or 99mTc-pertechnetate) – shows absent uptake in athyreosis and can reveal ectopic tissue elsewhere. Many centers perform both US and scintigraphy because the combination improves accuracy. Importantly, start levothyroxine promptly—imaging should not delay treatment. A knee X-ray may be added to estimate the severity of fetal hypothyroidism by assessing bone centers. PMC

Treatment

Levothyroxine (LT4) is the only recommended treatment for athyreosis. It replaces the missing thyroid hormone. Start as soon as congenital hypothyroidism is confirmed (and often immediately after a positive screen). Initial dose in term neonates is typically 10–15 micrograms per kilogram per day, given once daily; the dose is then adjusted to keep free T4 in the upper half of the reference range for age and TSH in the normal range. Follow-up labs are checked frequently during the first year. PMC+3Medscape+3NCBI+3

Because athyreosis is a complete absence of thyroid tissue, no surgery, no other “thyroid drugs,” and no supplement can replace LT4 or regrow a thyroid. Any source claiming otherwise conflicts with major guideline bodies. PubMed

---

Non-pharmacological supports (therapies & “other” care)

These do not treat athyreosis itself (only LT4 does), but they support best outcomes by protecting dosing, absorption, growth, and neurodevelopment.

1. Caregiver education (first day of treatment). Teach what athyreosis is, why LT4 is lifelong, how to give tiny tablets correctly, and why timing with feeds matters. Good understanding improves adherence and outcomes. PubMed

2. Newborn-to-infant follow-up schedule. Frequent checks of TSH/FT4 (e.g., 1–2 weeks after starting, then at regular intervals in infancy) allow quick dose adjustments, preventing under-treatment that could affect neurodevelopment. AAP Publications

3. Medication-timing coaching. LT4 works best on an empty stomach; avoid giving it with calcium/iron-rich feeds or supplements that block absorption. Simple routines (daily same-time dosing) reduce variability. PMC+1

4. Feeding support & lactation counseling. Help families integrate LT4 dosing around breastfeeding or formula. This reduces missed doses and avoids mixing tablets in calcium-fortified formulas that limit absorption. PMC

5. Avoid absorption blockers education. Space LT4 at least several hours from calcium, iron, soy, and high-fiber feeds; discuss common fortified foods (e.g., calcium-fortified juices). PMC+1

6. Newborn hearing screen & developmental surveillance. Even with early treatment, routine hearing checks and milestone tracking catch issues early and trigger early-intervention services if needed. PubMed

7. Early-intervention referral (as needed). If tone, feeding, or speech development lags, early PT/OT/speech services support motor and language gains during critical brain windows. (Guidelines emphasize neurodevelopmental monitoring.) PubMed

8. Simple pill-handling training. Teach caregivers to crush and give the tablet (not liquid compounded unless instructed) in a small amount of water or breast milk—not in a whole bottle—to ensure the full dose is taken. PubMed

9. Adherence aids. Use phone reminders, weekly pill boxes for caregivers, and written dosing charts to prevent missed or doubled doses, which can destabilize TSH/FT4 control. PubMed

10. Growth monitoring. Regular length/weight/head-circumference tracking helps confirm adequate thyroid replacement; faltering growth can be a clue to under-treatment or poor absorption. PubMed

11. Imaging-informed counseling. If ultrasound/scintigraphy shows no thyroid (athyreosis), explain that therapy is lifelong; this reduces future “trial off” requests that aren’t appropriate in agenesis. Emory School of Medicine

12. Genetic counseling (selected families). If there’s a family history of thyroid dysgenesis or dyshormonogenesis, discuss recurrence risk and testing options. PMC

13. Medication interaction review. If a breastfeeding parent or infant later needs medications that interfere with LT4 (e.g., iron, calcium, binders), plan spacing to protect LT4 absorption. PMC

14. Biotin caution. High-dose biotin (occasionally found in supplements) can distort thyroid blood tests; families should report any biotin use so labs aren’t misread. PMC

15. Public-health iodine literacy (for future pregnancies). While iodine deficiency is not the cause of athyreosis, adequate iodine in pregnancy prevents other forms of hypothyroidism and supports fetal brain development. PMC

16. Sick-day plan. During vomiting illnesses, discuss how to re-dose when a dose is lost and when to call the clinician; short lapses can be managed safely when addressed promptly. PubMed

17. Clear lab-goal education. Families should know the targets (FT4 high-normal for age; TSH in reference range) so they understand why frequent labs are essential early on. Medscape

18. Transition planning (toddlerhood and beyond). As doses shift with weight and age, plan periodic education “refreshers” to keep control steady. PubMed

19. Dental & airway awareness. Macroglossia and hypotonia improve with treatment, but routine dental/airway observations remain part of whole-child care. NCBI

20. Vaccinations & routine pediatric care. Standard immunizations and well-child visits continue on schedule; athyreosis/LT4 are not reasons to delay routine care. PubMed

---

Drug treatments

Evidence-supported therapy (recommended)

Levothyroxine (LT4). A synthetic T4 identical to the body’s hormone. Class: Thyroid hormone. Dose: Typically 10–15 mcg/kg/day orally once daily in term neonates; adjust by labs and growth. Timing: Start immediately after confirmatory testing (often right after a positive screen). Purpose & mechanism: Replaces missing thyroid hormone to normalize TSH/FT4 and protect brain development and growth. Side effects: Overtreatment can cause tachycardia, irritability, poor weight gain, and accelerated bone age; undertreatment risks neurodevelopmental harm. Key administration points: Give consistently, away from calcium/iron/soy/high-fiber to avoid reduced absorption. Medscape+2Pediatric Endocrine Society+2

Therapies that are not recommended for infants with athyreosis (with reasons)

The following are not evidence-based treatments for athyreosis and should be avoided unless a pediatric endocrinologist gives a specific indication. Listing them here helps prevent unsafe substitutions:

• Liothyronine (T3) or LT4/LT3 combinations (infants): not recommended in guidelines; babies need stable T4 to supply brain T3 locally. PubMed

• Desiccated thyroid products: variable T3/T4 content; not recommended in neonates/children. Pediatric Endocrine Society

• Iodine, antithyroid drugs, or “thyroid boosters”: no role; athyreosis is absence of tissue, not over/under-active tissue that can be “stimulated.” PMC

• Other routine “drugs” (probiotics, vitamins, etc.): do not treat athyreosis; they may interact with LT4 absorption (e.g., iron, calcium). PMC

(Because LT4 is the only drug therapy, it would be misleading and unsafe to fabricate “20 drug treatments.” The section above gives the one proven therapy and the key medications to avoid.)

---

Dietary molecular supplements

There is no supplement that treats athyreosis. Diet guidance focuses on preserving LT4 absorption and overall infant nutrition.

1. Breast milk or standard formula as primary nutrition. Supports growth; dose LT4 apart from feeds if calcium-fortified. PMC

2. Avoid simultaneous calcium (fortified juices/milks) near LT4 dose—space by several hours. Mechanism: calcium chelation reduces LT4 absorption. PMC

3. Avoid simultaneous iron (infant drops) near LT4 dose; iron forms complexes with LT4 in the gut. PMC

4. Be cautious with soy formulas/foods around dosing; soy can lower LT4 absorption—separate by hours. PMC

5. High-fiber mixes (e.g., cereal added to bottles) can impair absorption—avoid timing overlap. Mayo Clinic

6. Vitamin D per national infant guidance (for bone health) if recommended—does not treat athyreosis; time it away from LT4 if combined with calcium. PMC

7. Iodine: infants should receive normal dietary iodine via breast milk/formula; extra iodine is not a treatment and may be harmful—no supplementation beyond routine nutrition. PMC

8. Selenium: not a treatment for athyreosis in infants; avoid non-prescribed supplements. PubMed

9. Biotin: can distort thyroid labs; avoid high-dose products in the caregiver/infant around blood-test days unless discussed with the team. PMC

10. General rule: give only clinician-recommended infant vitamins; always space supplements from LT4 by several hours to protect absorption. PMC

---

Immunity booster / regenerative / stem-cell drugs

There are no approved immunity-boosting, regenerative, or stem-cell drugs that restore a missing thyroid in infants. Athyreosis = no thyroid tissue; current standard of care is lifelong LT4. Experimental regenerative thyroid approaches are not clinical care for newborns. Any claim to the contrary conflicts with international guidelines. PubMed

---

Surgeries

There is no surgery to treat athyreosis or to “implant a thyroid” in a baby. Surgery is not part of routine management. (Surgery may be considered in other thyroid conditions, like symptomatic ectopic/lingual thyroid—not applicable when the gland is absent.) Emory School of Medicine

---

Practical preventions

You can’t “prevent” athyreosis after birth, but you can prevent complications of undertreatment or poor absorption.

1. Start LT4 promptly after the screening/confirm tests. AAFP

2. Give LT4 daily, same time, with a simple routine that avoids food/supplement conflicts. PMC

3. Separate LT4 from calcium, iron, soy, and high-fiber feeds by several hours. PMC

4. Attend all lab follow-ups; early infancy needs frequent checks. AAP Publications

5. Use only LT4 tablets as prescribed; avoid switching to non-standard thyroid products. Pediatric Endocrine Society

6. Keep a dose-log to avoid missed/double dosing. PubMed

7. Tell clinicians about all meds/supplements that might reduce LT4 absorption. PMC

8. Monitor growth and milestones; report concerns early. PubMed

9. Imaging-based counseling: if agenesis confirmed, understand therapy is lifelong. Emory School of Medicine

10. Future pregnancy iodine adequacy for the family unit (public-health tip), even though it doesn’t prevent athyreosis specifically. PMC

---

When to see a doctor urgently vs. routinely

Urgently/soon: persistent vomiting with missed LT4 doses; very fussy/tachycardic (possible overtreatment); lethargy, poor feeding, hypothermia, or prolonged jaundice if not yet treated; any concern about incorrect dosing. Routinely: all scheduled labs/visits in the first year, dose checks after weight changes, and any time another medication/supplement is started. NCBI+1

---

What to eat and what to avoid

Eat: normal infant nutrition (breast milk or standard formula) on schedule; complementary foods as advised for age. Avoid at LT4 time: calcium-fortified milks/juices, iron drops, soy feeds, and high-fiber cereals at the same time as the LT4 dose—separate by several hours to protect absorption. Caregivers should also avoid giving LT4 with antacids or mineral supplements. PMC+1

---

FAQs

1) Is athyreosis curable?
No. The thyroid is absent. Lifelong levothyroxine safely replaces what’s missing. Genetic & Rare Diseases Center

2) Will my child grow and learn normally?
Yes—when treatment starts promptly and doses/labs are kept on track, outcomes are typically excellent. PubMed

3) What dose does a newborn need?
Usually 10–15 mcg/kg/day once daily, adjusted by labs and growth. Medscape

4) Tablet or liquid?
Guidelines favor tablets crushed and given properly; compounded liquids can vary. Follow your endocrinology team’s advice. PubMed

5) Can I mix the dose in a bottle?
No—babies may not finish the bottle. Give the crushed tablet in a tiny amount of liquid first, then feed. PubMed

6) Why separate LT4 from certain foods?
Calcium, iron, soy, and high fiber bind or block LT4, lowering absorption; separate by hours. PMC

7) How soon should labs improve?
With adequate starting dose, FT4 rises within about 2 weeks and TSH normalizes by about 1 month. AAFP

8) Do we need imaging?
Often yes, to define cause and guide counseling (e.g., agenesis vs. ectopic). Ultrasound and scintigraphy are complementary. Emory School of Medicine

9) Can we try “natural” thyroid or mix T3?
No—not recommended in infants; LT4 alone is standard. Pediatric Endocrine Society

10) What if a dose is vomited?
Call your care team for advice; short lapses are manageable if handled promptly. PubMed

11) Do vaccines affect thyroid treatment?
No—follow the routine schedule. PubMed

12) Can supplements change lab tests?
High-dose biotin can distort results; disclose any use before blood tests. PMC

13) Will dose change as my child grows?
Yes—LT4 is weight-based and adjusted with labs over time. NCBI

14) Is athyreosis genetic?
Most thyroid dysgenesis is sporadic; selected families may merit genetic counseling. PubMed

15) How common is congenital hypothyroidism?
It is the most frequent neonatal endocrine disorder; incidence varies by region and screening era. Frontiers

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 25, 2025.